Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth

Andreas Renner, Katharina Marth, Karin Patocka, Marco Idzko, Wolfgang Pohl
ERJ Open Research 2020 6: 00457-2020; DOI: 10.1183/23120541.00457-2020
Andreas Renner
1Karl Landsteiner Institute for Clinical and Experimental Pneumology, Hietzing Hospital, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andreas Renner
  • For correspondence: Andreas.renner@helsinki.fi
Katharina Marth
1Karl Landsteiner Institute for Clinical and Experimental Pneumology, Hietzing Hospital, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Patocka
1Karl Landsteiner Institute for Clinical and Experimental Pneumology, Hietzing Hospital, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Idzko
2Dept of Pulmonology, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Pohl
1Karl Landsteiner Institute for Clinical and Experimental Pneumology, Hietzing Hospital, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Experience with very mild #COVID19 disease courses in two severe eosinophilic asthmatics with complete eosinophil depletion due to benralizumab treatment counters the recent theories that eosinophilia is protective in COVID-19 infections https://bit.ly/3cnEFvg

To the Editor:

Amidst the current pandemic there is only little clinical evidence regarding COVID-19 infections in asthma patients. Chinese data suggests that asthma patients might not be at an elevated risk of severe infections [1, 2]. A recent article by Carli et al. [3] hypothesises that asthma might even have a protective effect in COVID-19 infections. It is important to point out that this is purely theoretical. Eosinophils from healthy probands have antiviral activity against respiratory syncytial virus and influenza virus, but not eosinophils collected from asthma patients [4]. Eosinopenia, alongside lymphopenia has been seen in COVID-19 patients [2]. Both eosinopenia and lymphopenia are more common in patients with COVID-19 pneumonitis compared with patients with non-COVID-19 viral pneumonitis [5]. Azkur et al. [6] attribute this to an overwhelming type 1 response.

Peters et al. [7] showed that angiotensin converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2), two molecules previously identified to facilitate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of host cells [8], have a higher expression in the sputum of certain asthma patients (African Americans, males and diabetics) and a lower expression in the sputum of asthma patients receiving inhaled corticosteroids, even when controlled for disease severity [7]. This provides rational for both potentially identifying at-risk populations and a protective effect of inhaled corticosteroids in asthma patients for COVID-19 infections that goes beyond improved asthma control. Kimura et al. [9] showed that interleukin (IL)-13, a mediator of T2 high asthma and a target of the monoclonal antibody (mAB) dupilumab, decreases ACE2 and increases TMPRSS2, possibly resulting in a zero-sum effect.

The current evidence on asthma, eosinophilia, T2 inflammation, and COVID-19 from preclinical and epidemiological data paints contradicting pictures. The work of Sabogal Piñeros et al. [4] suggests that eosinophils in asthmatics and non-asthmatics are not comparable in the context of viral infections. While the evidence for COVID-19 infections in severe asthma patients receiving mABs is only anecdotal, we believe that some important observations can be made.

In their recent publication, Förster-Ruhrmann et al. [10] presented the case of a mild COVID-19 infection in a patient receiving dupilumab for severe chronic rhinosinusitis with nasal polyps (CRSwNP). Based on the information provided in the case report it can be assumed that the patient suffers from aspirin-exacerbated respiratory disease, a distinct subtype of eosinophilic asthma. The authors hypothesised that an increase in blood eosinophils, a well-known effect of dupilumab treatment, might have had a protective effect during the COVID-19 infection. This misconception, based on a paper by Liu et al. [11], has led some to argue for the discontinuation of anti-IL-5/5R mABs in severe eosinophilic asthma patients. This has been strongly discouraged in a recent position paper by Shaker et al. [12].

Two severe eosinophilic asthma patients receiving benralizumab at our severe asthma clinic have had COVID-19 infections. Both patients experienced a very mild disease course with minimal to no deterioration in asthma control. The case report of a 41-year-old male patient has recently been published by Renner et al. [13]. A 66-year-old male patient with severe eosinophilic asthma and CRSwNP has received benralizumab since December 2018. Baseline blood eosinophilia before initiation of benralizumab was 380 cells·μL−1. Similar to our recently published case report, blood eosinophils were depleted immediately (20 cells·μL−1 24 h after treatment initiation, no detectable eosinophils thereafter) and asthma control improved rapidly (asthma control test 11 before treatment and >20 after treatment).

On 28 March 2020 the patient developed fever, anosmia and fatigue. Two SARS-CoV-2 PCR tests were taken on two different days, both were positive. The fever improved after a few days, anosmia and fatigue lasted 2 weeks. The patient did not experience any pulmonary symptoms, asthma control test and asthma control questionnaire 6-item scale were unchanged from before the infection (25 and 0, respectively). No increase in asthma medication was necessary.

In our opinion, two assumptions can be made from viewing these three cases together.

The first concerns the potential protective effect of mAB treatment in these patients. While there is little evidence that people with asthma are at an elevated risk of more severe COVID-19 infections, both the patient presented here, as well as the patient in Renner et al. [13] regularly suffered from viral exacerbations before the initiation of benralizumab. Case reports, and even case series, only provide anecdotal evidence, but with a growing number of similar cases the strength of this evidence increases. We believe that this potential protective effect might be based on good asthma control rather than immunological mechanisms, which are different in benralizumab and dupilumab.

Secondly, both our patients had no detectable blood eosinophils due to benralizumab treatment at the time of COVID-19 infection. As pointed out in a recent review by Lindsley et al. [14] a protective effect of eosinophilia in COVID-19 infections seems unlikely. Thus, we believe that there is no protective effect of elevated blood eosinophils, at least in eosinophilic asthma patients, and that this did not contribute to the mild disease in the patient presented by Förster-Ruhrmann et al. [10].

More case studies, and if possible prospective data collections and formal analyses of severe eosinophilic asthma patients receiving mAB treatment with COVID-19 infections, are necessary to confirm the assumptions laid out above.

Footnotes

  • Conflict of interest: A. Renner has nothing to disclose.

  • Conflict of interest: K. Marth has nothing to disclose.

  • Conflict of interest: K. Patocka has nothing to disclose.

  • Conflict of interest: M. Idzko has nothing to disclose.

  • Conflict of interest: W. Pohl has nothing to disclose.

  • Received July 1, 2020.
  • Accepted September 15, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Zhou F,
    2. Yu T,
    3. Du R, et al.
    Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–1062. doi:10.1016/S0140-6736(20)30566-3
    OpenUrlCrossRefPubMed
  2. ↵
    1. Zhang J-J,
    2. Dong X,
    3. Cao Y-Y, et al.
    Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75: 1730–1741. doi:10.1111/all.14238
    OpenUrlCrossRefPubMed
  3. ↵
    1. Carli G,
    2. Cecchi L,
    3. Stebbing J, et al.
    Is asthma protective against COVID-19? Allergy 2020; in press [https://doi.org/10.1111/all.14426]. doi:10.1111/all.14426
  4. ↵
    1. Sabogal Piñeros YS,
    2. Bal SM,
    3. Dijkhuis A, et al.
    Eosinophils capture viruses, a capacity that is defective in asthma. Allergy 2019; 74: 1898–909. doi:10.1111/all.13802
    OpenUrl
  5. ↵
    1. Li YX,
    2. Wu W,
    3. Yang T, et al.
    [Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19]. Zhonghua Nei Ke Za Zhi 2020; 59: E003.
    OpenUrl
  6. ↵
    1. Azkur AK,
    2. Akdis M,
    3. Azkur D, et al.
    Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020; 75: 1564–1581. doi:10.1111/all.14364
    OpenUrlCrossRefPubMed
  7. ↵
    1. Peters MC,
    2. Sajuthi S,
    3. Deford P, et al.
    COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med 2020; 202: 83–90. doi:10.1164/rccm.202003-0821OC
    OpenUrl
  8. ↵
    1. Hoffmann M,
    2. Kleine-Weber H,
    3. Schroeder S, et al.
    SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271–280. doi:10.1016/j.cell.2020.02.052
    OpenUrlCrossRefPubMed
  9. ↵
    1. Kimura H,
    2. Francisco D,
    3. Conway M, et al.
    Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol 2020; 146: 80–88. doi:10.1016/j.jaci.2020.05.004
    OpenUrl
  10. ↵
    1. Förster-Ruhrmann U,
    2. Szczepek AJ,
    3. Bachert C, et al.
    COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab. J Allergy Clin Immunol 2020; 146: 218–220.e2. doi:10.1016/j.jaci.2020.05.005
    OpenUrl
  11. ↵
    1. Liu F,
    2. Xu A,
    3. Zhang Y, et al.
    Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis 2020; 95: 183–191. doi:10.1016/j.ijid.2020.03.013
    OpenUrlPubMed
  12. ↵
    1. Shaker MS,
    2. Oppenheimer J,
    3. Grayson M, et al.
    COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic. J Allergy Clin Immunol Pract 2020; 8: 1477–1488. doi:10.1016/j.jaip.2020.03.012
    OpenUrl
  13. ↵
    1. Renner A,
    2. Marth K,
    3. Patocka K, et al.
    COVID-19 in a severe eosinophilic asthmatic receiving benralizumab - a case study. J Asthma 2020; in press [https://doi.org/10.1080/02770903.2020.1781165]. doi:10.1080/02770903.2020.1781165
  14. ↵
    1. Lindsley AW,
    2. Schwartz JT,
    3. Rothenberg ME
    . Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol 2020; 146: 1–7. doi:10.1016/j.jaci.2020.04.021
    OpenUrlPubMed
PreviousNext
Back to top
Vol 6 Issue 4 Table of Contents
ERJ Open Research: 6 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
Andreas Renner, Katharina Marth, Karin Patocka, Marco Idzko, Wolfgang Pohl
ERJ Open Research Oct 2020, 6 (4) 00457-2020; DOI: 10.1183/23120541.00457-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
Andreas Renner, Katharina Marth, Karin Patocka, Marco Idzko, Wolfgang Pohl
ERJ Open Research Oct 2020, 6 (4) 00457-2020; DOI: 10.1183/23120541.00457-2020
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Pulmonary pharmacology and therapeutics
  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • rs2070600 SNP regulates AGER splicing and sputum sRAGE
  • Expression profiling by RNA-Seq in bronchial biopsies of COPD patients
  • Procoagulant microparticles and COVID-19
Show more Original research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society